{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:41:56Z","timestamp":1740184916652,"version":"3.37.3"},"reference-count":21,"publisher":"Chinese Center for Disease Control and Prevention","issue":"49","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.46234\/ccdcw2023.207","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:06:04Z","timestamp":1702047964000},"page":"1107-1114","source":"Crossref","is-referenced-by-count":1,"title":["eALT-F: A New Non-Invasive Staging Method to Identify Medium to High-Risk Patients with HCC from Ultra-High HBV Viral Load Population \u2014 China, 2010\u20132023"],"prefix":"10.46234","volume":"5","author":[{"given":"Jiarui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Peking University People\u2019s Hospital, Peking University Hepatology Institute, Beijing, China","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yandi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzhen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Peking University People\u2019s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing, China","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"25413","reference":[{"key":"1","unstructured":"Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (Version 2022). Chin J Infect Dis 2022;30(12):1309 \u2212 31.  http:\/\/dx.doi.org\/10.3760\/cma.j.cn501113-20221204-00607.  (In Chinese)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Martin P, Nguyen MH, Dieterich DT, Lau DTY, Janssen HLA, Peters MG, et al. Treatment algorithm for managing chronic hepatitis b virus infection in the united states: 2021 update. Clin Gastroenterol Hepatol 2022;20(8):1766 \u2212 75.  http:\/\/dx.doi.org\/10.1016\/j.cgh.2021.07.036.","DOI":"10.1016\/j.cgh.2021.07.036"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Nguyen VTT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009;16(7):453 \u2212 63.  http:\/\/dx.doi.org\/10.1111\/j.1365-2893.2009.01117.x.","DOI":"10.1111\/j.1365-2893.2009.01117.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295(1):65 \u2212 73.  http:\/\/dx.doi.org\/10.1001\/jama.295.1.65.","DOI":"10.1001\/jama.295.1.65"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Meng C, Liu T, Liu YW, Zhang LZ, Wang YL. Hepatitis B virus cccdna in hepatocellular carcinoma tissue increases the risk of recurrence after liver transplantation. Transplant Proc 2019;51(10):3364 \u2212 8.  http:\/\/dx.doi.org\/10.1016\/j.transproceed.2019.04.020.","DOI":"10.1016\/j.transproceed.2019.04.020"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Yang Y, Wen F, Li JL, Zhang PF, Yan WH, Hao P, et al. A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib. Liver Int 2015;35(9):2147 \u2212 54.  http:\/\/dx.doi.org\/10.1111\/liv.12805.","DOI":"10.1111\/liv.12805"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Klair JS, Vancura J, Murali AR. PRO: Patients with chronic hepatitis B in immune-tolerant phase should be treated. Clin Liver Dis (Hoboken) 2020;15(1):21 \u2212 4.  http:\/\/dx.doi.org\/10.1002\/cld.892.","DOI":"10.1002\/cld.892"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol 2020;73(6):1368 \u2212 78.  http:\/\/dx.doi.org\/10.1016\/j.jhep.2020.07.025.","DOI":"10.1016\/j.jhep.2020.07.025"},{"key":"9","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017;67(2):370 \u2212 98.  http:\/\/dx.doi.org\/10.1016\/j.jhep.2017.03.021.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Stella L, Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: from molecular pathways to the role of clinical surveillance and antiviral treatment. World J Gastroenterol 2022;28(21):2251 \u2212 81.  http:\/\/dx.doi.org\/10.3748\/wjg.v28.i21.2251.","DOI":"10.3748\/wjg.v28.i21.2251"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Liaw YF. Perspectives on current controversial issues in the management of chronic HBV infection. J Gastroenterol 2022;57(11):828 \u2212 37.  http:\/\/dx.doi.org\/10.1007\/s00535-022-01918-z.","DOI":"10.1007\/s00535-022-01918-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hong YM, Yoon KT. Definition and management of the immune tolerance phase in chronic hepatitis B. Korean J Gastroenterol 2022;79(4):156 \u2212 60.  http:\/\/dx.doi.org\/10.4166\/kjg.2022.049.","DOI":"10.4166\/kjg.2022.049"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012;143(3):637 \u2212 45.  http:\/\/dx.doi.org\/10.1053\/j.gastro.2012.06.009.","DOI":"10.1053\/j.gastro.2012.06.009"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Huang DQ, Li XH, Le MH, Le AK, Yeo YH, Trinh HN, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol 2022;20(8):1803 \u2212 12.e5.  http:\/\/dx.doi.org\/10.1016\/j.cgh.2021.01.019.","DOI":"10.1016\/j.cgh.2021.01.019"},{"key":"15","unstructured":"Zhuang H. Should patients in the immune tolerance stage of chronic hepatitis B virus infection be treated? J Clin Hepatol 2021;37(2):272-7. <a href=\"http:\/\/dx.doi.org\/10.3969\/j.issn.1001-5256.2021.02.007\">http:\/\/dx.doi.org\/10.3969\/j.issn.1001-5256.2021.02.007<\/a>. (In Chinese)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"Liu JC, Wang J, Yan XM, Xue RF, Zhan J, Jiang SL, et al. Presence of liver inflammation in asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol Commun 2022;6(4):855 \u2212 66.  http:\/\/dx.doi.org\/10.1002\/hep4.1859.","DOI":"10.1002\/hep4.1859"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67(1):6 \u2212 19.  http:\/\/dx.doi.org\/10.1136\/gutjnl-2017-314924.","DOI":"10.1136\/gutjnl-2017-314924"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Kaya A, Barutcu S, G\u00fclsen MT. Evaluation of fibrosis with noninvasive biochemical tests in chronic viral hepatitis B. Hepatol Forum 2023;4(1):25 \u2212 9.  http:\/\/dx.doi.org\/10.14744\/hf.2022.2022.0025.","DOI":"10.14744\/hf.2022.2022.0025"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, et al. One-year fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15(1):105 \u2212 13.  http:\/\/dx.doi.org\/10.1007\/s12072-020-10124-z.","DOI":"10.1007\/s12072-020-10124-z"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 2018;67(5):945 \u2212 52.  http:\/\/dx.doi.org\/10.1136\/gutjnl-2017-314904.","DOI":"10.1136\/gutjnl-2017-314904"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Fan R, Li GL, Yu N, Chang XJ, Arshad T, Liu WY, et al. Amap score and its combination with liver stiffness measurement accurately assess liver fibrosis in chronic hepatitis B patients. Clin Gastroenterol Hepatol 2023;21(12):3070 \u2212 9.e13.  http:\/\/dx.doi.org\/10.1016\/j.cgh.2023.03.005.","DOI":"10.1016\/j.cgh.2023.03.005"}],"container-title":["China CDC Weekly"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/weekly.chinacdc.cn\/en\/article\/pdf\/preview\/10.46234\/ccdcw2023.207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:06:13Z","timestamp":1702047973000},"score":1,"resource":{"primary":{"URL":"https:\/\/weekly.chinacdc.cn\/en\/article\/doi\/10.46234\/ccdcw2023.207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":21,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.46234\/ccdcw2023.207","relation":{},"ISSN":["2097-3101"],"issn-type":[{"type":"print","value":"2097-3101"}],"subject":[],"published":{"date-parts":[[2023]]}}}